CLINICAL ROLE -
Data Suggest Combination Abilities of OP-1250, Palbociclib for Breast Cancer at SABCS
OP-1250 and palbociclib showed “enhanced suppression of tumor growth” in preclinical mouse model studies, according to expert who presented his findings in a poster at the San Antonio Breast Cancer Symposium 2022.
Real World Testing May Help Better Understand Inconsistent Medicine Adherence in Clinical Trials
Dawn L. Hershman, MD, MS, Columbia University Medical Center, New York, NY, presents her findings at the 2022 San Antonio Breast Cancer Symposium.
New Drug Could Change Treatment Landscape for ER-Positive, HER2-Negative Breast Cancer
Researchers discovered the most common single gene mutation that causes treatment-resistance in first- line ER-positive or HER2-negative breast cancer treatment with a CDK4/6 inhibitor.
FDA Targets Drugmakers Accused of Blocking Generics
FDA officials are publicizing information on brand name drugmakers that use what government officials call “gaming tactics” to block cheaper generic versions.
2 Clarke Drive Cranbury, NJ 08512